An investigational breast cancer vaccine produced an immune response in 74% of clinical trial participants, according to data being presented at the San Antonio Breast Cancer Symposium.
Cleveland Clinic researchers conducted the phase 1 clinical trial, which enrolled 35 patients across three cohorts, according to a Dec. 11 news release from the health system.
The three cohorts included: patients who completed treatment for early-stage, triple-negative breast cancer within the previous three years and were tumor-free but at high risk for recurrence; cancer-free individuals who carry genetic mutations associated with elevated breast cancer risk and elected to have a preventative mastectomy; and early-stage triple-negative breast cancer patients who received pre-operative chemoimmunotherapy and surgery, and were treated with pembrolizumab.
A phase 2 trial for the vaccine is expected to begin in 2026 and last two to three years, the release said.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
